By: LISA R. WILSON
The latest slew of overturned verdicts against Merck, the makers of the withdrawn painkiller Vioxx, is yet another indication of the increasing difficulty that plaintiffs’ lawyers are experiencing in winning lawsuits against big drug companies. The latest ruling overturned a $26 million jury verdict against Merck in Texas based on the grounds [...]
Entries Tagged as 'Vioxx'
Fighting an uphill battle:
Vioxx verdicts are being overturned
July 8th, 2008 · 1 Comment
Tags: Catastrophic Injury · Class Actions · Dangerous Products / Defective Products · Drugs · Federal · Lead Counsel Corner · Lead Counsel News · Litigation · Products Liability · Vioxx · Wrongful Death
Merck in more Hot Water over Vioxx
April 25th, 2008 · 2 Comments
Pharmaceutical company Merck is currently fighting lawsuits brought by patients of their drug Vioxx, who claim the drug caused them to suffer severe health complications such as heart attacks and strokes. However, new allegations suggest that Merck may have known about the propensity of the drug to cause these health complications and kept the [...]
Tags: Class Actions · Personal Injury · Products Liability · Vioxx · Wrongful Death
Summary: Merck Wins Latest Vioxx Trial
July 13th, 2006 · 3 Comments
Politics, juries will vary verdicts for Vioxx attorneys
September 23rd, 2005 · 1 Comment
Issues in Tort LawBy Attorney David I. Fuchs
As trials continue against Merck, the maker of Vioxx, attorney David I. Fuchs predicts a change in verdicts from state to state, based on the political views of the jury in each jurisdiction.
In South Florida, where Fuchs practices law, juries tend to be much more conservative in their [...]
Tags: Vioxx
FDA issues warnings about more pain relievers
April 7th, 2005 · 2 Comments
The U.S. Food & Drug Administration said yesterday that warnings about heart or stomach risks must be placed on all pain relievers in a class called “non-steroidal anti-inflammatory drugs.” It excluded aspirin and acetaminophen, which is sold under the brand name Tylenol.
FDA urges Pfizer to pull Bextra from shelves, issues Celebrex, Vioxx warning
April 7th, 2005 · 2 Comments
The Food and Drug Administration has asked Pfizer to voluntarily remove Bextra (valdecoxib) from the market. FDA is also asking manufacturers of all marketed prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Celebrex (celecoxib), to revise their products to include a boxed warning, highlighting the potential for increased risk of cardiovascular (CV) events and the well-described, [...]
Lindsey O'Neill is the Director of Legal Content and Strategic Development at LawInfo.com. Ms. O'Neill is a California licensed attorney based in La Jolla and experienced in a wide variety of legal and business matters.